Alto Neuroscience, INC Form 4 insider transactions

Director Andrew Craig Miller was granted 26,000 stock options as part of the company's non-employee director compensation policy.

Alto Neuroscience's President and CEO, Amit Etkin, gifted 400,000 shares of common stock to an irrevocable trust for estate planning purposes.

Ramiro Sanchez, a Director at Alto Neuroscience, Inc., acquired 10,958 stock options with an exercise price of $24.63.

Alto Neuroscience Director Christopher Nixon Cox acquired stock options, as disclosed in a Form 4 filing.

Alto Neuroscience, Inc. director Manji Husseini acquired 10,958 stock options with an exercise price of $24.63.

Alto Neuroscience, Inc. director Andrew Dreyfus acquired stock options, as disclosed in a Form 4 filing.

Alto Neuroscience, Inc. reports that Director York Gwill was granted stock options on May 12, 2026, as part of the company's Non-Employee Director Compensation Policy.

Alto Neuroscience's President and CEO, Amit Etkin, was granted 306,000 employee stock options with an exercise price of $16.71, vesting over four years.

Alto Neuroscience's Chief Medical Officer, Adam Savitz, was granted 124,000 employee stock options with an exercise price of $16.71.

Alto Neuroscience, Inc.'s Chief Financial Officer and Chief Business Officer, Nicholas Conrad Smith, was granted 200,000 employee stock options.

Alto Neuroscience's Chief Operating Officer, Michael Conick Hanley Jr., acquired 131,000 employee stock options with an exercise price of $16.71.

Alto Neuroscience, Inc. director Gwill York was granted 5,243 stock options as part of the company's non-employee director compensation policy.

Alto Neuroscience Director Christopher Nixon Cox was granted 7,189 stock options in lieu of $85,000 in retainer fees, vesting quarterly throughout 2026.

Alto Neuroscience director Husseini Manji was granted 4,228 stock options with an exercise price of $16.59, vesting quarterly through 2026.

Alto Neuroscience, Inc. Director Ramiro Sanchez was granted 3,806 stock options with an exercise price of $16.59, vesting quarterly throughout 2026.

Alto Neuroscience Director Ramiro Sanchez received stock options for 34,502 shares as part of the company's non-employee director compensation policy.

Alto Neuroscience, Inc. has repriced 321,000 employee stock options for its Chief Operating Officer, Michael Conick Hanley Jr., to an exercise price of $2.35 per share, effective July 3, 2025, aligning with the closing stock price on that date.

Alto Neuroscience, Inc. has repriced stock options for its Chief Medical Officer, Adam Savitz, and other continuing employees, lowering the exercise price to $2.35 per share to align with current market value and enhance retention.

Alto Neuroscience, Inc. has repriced stock options for its President and CEO, Amit Etkin, to an exercise price of $2.35 per share, effective July 3, 2025, impacting over 700,000 shares.

Alto Neuroscience, Inc. has repriced stock options for its Chief Financial Officer, Nicholas Conrad Smith, lowering the exercise price to $2.35 per share for over 500,000 options.

Director Andrew Dreyfus acquired stock options for 15,287 shares of Alto Neuroscience, Inc. on May 13, 2025, as part of the company's Non-Employee Director Compensation Policy.

Director Gwill York acquired stock options in Alto Neuroscience, Inc. on May 13, 2025, according to a Form 4 filing.

Director Husseini Manji acquired stock options in Alto Neuroscience, Inc. on May 13, 2025, according to a Form 4 filing.

Christopher Nixon Cox, a director at Alto Neuroscience, acquired stock options for 15,287 shares of common stock on May 13, 2025.

Michael Conick Hanley Jr., Chief Operating Officer of Alto Neuroscience, Inc., was granted employee stock options for 125,000 shares on February 5, 2025.

Nicholas Conrad Smith, CFO of Alto Neuroscience, acquired 135,000 employee stock options on February 5, 2025.

Adam Savitz, Chief Medical Officer of Alto Neuroscience, acquired 76,000 employee stock options on February 5, 2025, according to a Form 4 filing.

CEO of Alto Neuroscience, Amit Etkin, reports the acquisition of 215,000 employee stock options.

Alto Neuroscience director, Gwill York, acquired 19,558 stock options in lieu of $62,000 in retainer fees.

Husseini Manji, a director at Alto Neuroscience, acquired stock options for 14,195 shares in lieu of $45,000 in retainer fees.